





> Sleep Diagnostics

> Brain Research -> Neurodiagnostics

> Doppler Sonography

> Neuromedical Supplies

Annual General Meeting • October 2005

Agenda

- Meeting opens
- Chairman's address
- Ordinary business and acceptance of Remuneration Report
- Commendation to Ko Koike for his dedication to the Board and his valuable years of service. Special thank you from the Chairman, Board and staff
- Meeting closes



Chairman's Address



Outline

- 1. Financial review June 30, 2005.
- 2. Review of the past year.
- Key strategies.
- 4. Key milestones.
- 5. The road forward.



Financial Review - June 30,2005

- Record revenues of \$38m compared to last year's \$34m.
- DWL acquired and included in results for 10 months.
- Underlying sleep, EEG and Neuroscan businesses performed below expectations.
- Changes have occurred and are showing early signs of working, being the employment of:
 - VP Sales, America's
 - VP Marketing, America's
 - iii. Business Director, Asia
 - iv. Business Manager, Asia
 - v. Business Director, Europe and Middle East



Corporate Profile

- Over 1,400 beds of sleep diagnostics installed in the USA.
- No 1 market leader in Brain research in the USA.
- No 1 market leader in sleep diagnostics in Japan.
- No 1 market leader position in sleep diagnostics (70% share) in Australia.
- No. 1 market leader position in clinical EEG (40% share) in Australia.
- No. 1 market leader position in sleep diagnostics in China.
- Emerging market presence in Europe.
- No. 3 market position in USA (largest world's medical device market) but highest growth outlook.



Corporate Profile

- Proprietary technology in three high growth emerging markets.
- Existing business, with proven technologies and products.
- Existing business with significant proven organic growth
 - Significant expansion opportunities into:
 - **"** USA
 - Europe
 - Asia
 - The Company has increased its sales more than 4-fold from \$9 million to \$38 million, reflecting its continued commitment to an effective sales and R&D organisation.
 - Compumedics' equipment is distributed in 60 countries globally. Headquarters are in Melbourne, Australia with offices in Germany, Singapore, Japan and the USA.



Corporate Profile—the markets

- Compumedics operates in the following emerging high growth markets:
 - Sleep disorders
 - 80% sleep diagnostic market share in Australia
 - 12% sleep diagnostic market share in the USA and growing
 - Major market share in Japan
 - Emerging market share in Europe
 - Neurophysiology
 - 70% brain research market share in USA
 - 60% market share in clinical EEG in Australia
 - Growing research market share in Asia, particularly China
 - Dominant research market in the UK, emerging in Germany
 - Opportunities in EMG
 - Blood flow through the brain
 - Proprietary technology invented by Rune Aslid and DWL
 - Market leader in Germany
 - Emerging positions in USA and Asia



Corporate Profile – existing business

- Compumedics has been trading since 1987.
- Compumedics has sold direct in the USA since 2002, with significant opportunity for future growth still to be realised.
 - USA growth complimented by Asian and European opportunities, particularly China, Germany and France.
 - Strong revenue growth already achieved 33% compound over the last 5 years.
- Strong R&D focus with significant investment over the last two years at close to 20% of revenues.
 - Future focus on earnings consistency and earnings growth.



Overview – Key Milestones

Compumedics has an impressive track record of achievement:

or
ļ

- 1995 Sleep Heart Health Study awarded
- 1997 FDA approval for the P-Series
- 1999 2000 FDA approval for EEG device
- 2000 ASX listing
- 2002 USA business moves to solely direct sell to end customers
- 2002 Neuroscan acquisition, \$8m revenue achieved in 2004 from SynAmps2
- 2002 New factory opened
- 2003 FDA approval for Somte Sleep/CHF device
- 2005 The pre-eminent American Academy of Sleep is reviewing a possible change in the sleep scoring protocol. The majority of the committee members use Compumedics equipment
- 2005 Over 1,500 universities, corporate laboratories and national research centres use Neuroscan,
 2,000 CMP sleep systems, 6,000 DWL systems, 12,000 systems worldwide
- 2005 Over 50 countries worldwide have access to Compumedics technology
 - 2005 Sleep Heart Health Study CMP equipment is being used in 14-year study 20.000 patients to 2008



2004 Deloitte Technology Fast 50

2003 Frost & Sullivan Award for Market Expansion

2003 David Burton-Centenary Medal

2002 David Burton-Clunies Ross National Science and

Technology Award

2001 Governor of Victoria Export Award for Small to Medium

Manufacturer

1999 Small Business of the Year at the Telstra and Victorian Govt. Small Business Awards

COMPLIANTOCS



Introduction

Clients of Compumedics



Chants

novite di Motorero Manie

SERBLOI CESSERVAND (FOR)

ZPROGODNIZO CERRIO (ALIXO)

ekonsek Copins királozások

Salaci of Weighted avid Mi

sa Carbona én Linguas a

Chrenta

ry mad i modal spanoskagas jostánamatimpana 2 fina awayong

ामचे १९ व्यवस्था व्यक्ति । उत्तरभाषीय देखाः अविधानम ou atem ser ceico é hebre curebi i de PROBLEM STANDARD (SEE MARS SCHOOLS PROPERTY

itsifiqaabuutens A.-Canaad Bergabal Bisadi

enti filodocal Centro (Isani)

el Chichien, Bospiel Card

eli dundorigi irdininati (iiki

ender Gerrand United GISAS

word Civer of Buryard GISS

of Prince discollingular Gentl

Sanda Cimaboa Biogrés (dusa)

xasaby kil Caliberria is San Diropa SISI

zmaty of the ext. Should be regalated that

Bolden of Anglish of Francis - Shop Horst

walne BBS Bland 6991 shashu

visco (Childron) sub-ingropiosi ilistrae den isessi:

aparija di Christopira, Cursa Rava). airs Kaskaay Carka (1873)


ซีสาร ที่ได้ตัดสาราธิต สำเหาสัง

zeriek al Sydemy (berá)

rowanies (dead)

sterkinika la Bangmus Laborakoty ducts Provided: ARRESE -- RECIBE SERVER BEVERFÜL BERRE n x aci ca walikar e daha adiga sekkan ndiberah.

Compoundation is context Boll to the fastest growing Sleenmarket, the US - worth approach



"House aged Meioreacon oraphibes orehedisone for the post Hit powers and convently non Neumescan Syronrya 201 Structure and Syronrya 2019 anydiffers. Charages neclass these desired assertions at Secretary. Sitter (** and Preferbosion** software pauckages and the Northwest Abelia in Stranger in several Will funded skeeps reason of priodects. As a cheep researcher, it as a excited allows the follow prospects of Companionsian

Meuro Diagnostics AUGUSTANI JAROMAININE

> Nettin Medical Supplies

CONTRACTOR STATE



Exciting opportunities

exist in the massive Neuro

Diagnostics market worth:

- Products provided Bando 1960 - Baradaania armaaksis Jamp SCHOOL OFFICE
- Sastád szákás telépetésád tarráb SESSORIO PY WYSIANIE
- 1 Session (ECVP92) receive submeredly. delegación y usua com balde diferen e seciena Salato 1990 – sásoni kar maksakátak y -segalicoli meny manifologi
- 15 Santon partodo lo casago reacostar prendica NOON was bloop liquit has his known

condousing the takens and expertise of its

Nexus expansional Skrap divisions to procince what will random be silv become the new gold manched technology for despitoscaph."

Ber San, Graba hir salamata kwa takwa Lisanga di kanawani Programmati 1999. Na Silanga Pente, Carabina tan benjeni 2001, Program sa Principa. Da Carabina sanawan. ssim i Brisani Novinia Bharachti Schoolsis ad Somotheric hisagis Hose the a Comb. Co. Column is also Province (Federal exist Assection) Province in than I happen thrown and Step trading proof them the block working and belief to a cros-

Nov Charts

- History Medical Cardo Marcirestinifequiuminus di Conece i inequali
- Sá, knemmén iánnosa i shasá)
- Regulation are the appear of the p - Konnikarana ikapasi ining
- Repailing Bulkergrade Mach
- Princes Margari Hoggins Santi – Rovejskess Sässe ikséréske Örfel

If selects Provided

- I berievi (EII) is instatu visity is income poviouse 66 Kircheleiese Saltaco e 7 6% - La gardinca vicilida un live
- amándakay, appánakasa. Steph P. C. The obtable in edicates. czątekoláten an EE S



Koy Clisuis Wiften (Samerakan ASA) Massa-Mitoraccii Ceessor §3563

- Eusteser Medera: (1996)

Products provided Our comparison electron appell products pacces ad titr they resided use t

Chart Scanner 641689 549000 MC/floring - Mackades

PROJECT TO BASEBOOK COOKS BUSING

Newsity, Model

DWL: Acquisition – an update

- DWL business is up and running.
- Complementary brain function technology based on Doppler Sonography.
- Building our base in Europe.
- 60% market share in Germany.
- Good opportunity to globalise technology.
- Sales to be approximately \$6m in 2006.



Performance relative to previous period

\$Am	12 mths to June 30 2003	12 mths to June 30 2004	12 mths to June 30 2005
Operating Revenue	32.1	34.0	38.2
EBITDA	1.9	2.9	(2.6)
EBIT	(18.8)	2.4	(3.9)
Profit after Tax	(18.6)	2.4	(3.9)
Gross Margin	57%	59%	53%
EBITDA/Op. Revenue	6%	9%	(7%)
Profit after tax/Op. Revenue	n/a	7%	(10.2)



Balance Sheet relative to PCP

	June 2005 A\$'000	June 2004 A\$'000	
CURRENT ASSETS Cash assets Receivables Inventories Other	3,922 11,239 5,963 426	6,352 10,239 6,481 69	
Total current assets NON CURRENT ASSETS Other	21,549 119	23,141	
Property, plant and equipment Intangible assets TOTAL ASSETS	1,521 1,361 24,549	1,368 - 24,509	
CURRENT LIABILITIES Payables Interest bearing liabilities Provisions Other	7,456 1,391 535 1,150	4,123 1,884 892 1,330	
Total current liabilities NON CURRENT LIABILITIES	10,531 4,671	8,229 2,335	
TOTAL LIABILITIES	15,202	10,564	
NET ASSETS	9,347	13,945	



Siide 14

Financial Performance

Costs under focus

Investments in new sales and marketing resources have been made so the company will continue to be vigilant with monitoring its expenses whilst these incremental expenses bear fruit through greater sales.

Margins

- June 04 57%, June 05 53%.
- A renewed focus on margins is currently being implemented to restore margins to their previous levels.
- Working capital improving
 - Debtors days were impacted by skewing of sales to the month of June.
 - Inventory still needs work but improving.




First quarter trading performance

Due to the end of September sales not being as strong as anticipated in the company's financial modeling, the company is not compliant with one of several covenants in its bank facility as at the end of the September quarter. The bank has expressed ongoing support for the company and its strategy for financial performance recovery and growth.

The company has taken out over \$1 m of annualized costs from the business and specific other costs from other parts of the business amounting to at least \$0.75m and these cost reduction initiatives coupled with the revenue growth strategies previously disclosed will strengthen earnings of the company and are anticipated to restore compliance with bank covenants during the course of 2006



Historical Sales Graph



Fact:


Revenues for the last five years have grown an average:

+ 33% p.a.



'Defining Life't Signals'

International expansion continues





Plenty of room to grow:

Global Brain Research market AS:

\$70M

Global Sleep Diagnostics market As: \$250M

2001

\$260M



Strategy Working

Building a global medical diagnostic company

- With Compumedics' core strategic edge being Sleep Diagnostics and
- Leveraging this technology into related fields including Neurosciences and Cardiology.




Moving Forward: Business

- Revenues expected to continue growing beyond \$38million for year ended June 30, 2006.
- Margins have improved since June 2005.
- Earnings to be restored during the financial year.
- Research and development expenditure expected to be between 16% and 18% of revenue, for year ended June 30, 2006.
- **n** The cost efficiency programs are delivering results.
- Expanded and strengthened USA sales force with more new sales territories, and new VP Sales, America's and VP Marketing America's.
- New leadership in Asia and Europe strengthening business there.



Moving Forward: Technologies









Curry 5.0 Siesta802 ComperioDQ

Stim II

COMPLIMEDICS



- Strong product pipelines in all CMP divisions.
- Medical Innovation breakthroughs now in patent and clinical proof of concept phase.

Recap

- Business has instigated a major restructure in the last 9 months which is now beginning to contribute to the underlying performance.
- 2 Q1 results were strong in Asia, Australia and Europe and emerging in the USA, this held Q1 numbers back.
- 3 Clear focus on costs and profitability, while sustaining ongoing growth.
- 4. Opportunities in DWL for existing business and its emerging technologies.



Ordinary business

- Mr. Ko Koike has resigned as a Director for health reasons.
- Mr. Alan Anderson who retires by rotation offers himself for re-election to the position of Non-Executive Director.
- Non binding vote on remuneration report.



'Defining Life's Signals'





Thank You